SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 1993. Upgrade now.
Date Value
December 31, 2023 293.90M
September 30, 2023 267.90M
June 30, 2023 283.90M
March 31, 2023 315.60M
December 31, 2022 272.80M
September 30, 2022 266.50M
June 30, 2022 253.30M
March 31, 2022 209.60M
December 31, 2021 226.16M
September 30, 2021 190.70M
June 30, 2021 168.90M
March 31, 2021 153.80M
December 31, 2020 167.00M
September 30, 2020 120.80M
June 30, 2020 118.00M
March 31, 2020 111.10M
December 31, 2019 136.21M
September 30, 2019 102.60M
June 30, 2019 105.90M
March 31, 2019 123.98M
December 31, 2018 108.36M
September 30, 2018 96.52M
June 30, 2018 108.03M
March 31, 2018 121.50M
December 31, 2017 97.73M
Date Value
September 30, 2017 91.26M
June 30, 2017 90.07M
March 31, 2017 87.23M
December 31, 2016 96.08M
September 30, 2016 75.78M
June 30, 2016 66.79M
March 31, 2016 64.60M
December 31, 2015 52.47M
September 30, 2015 47.60M
June 30, 2015 51.68M
March 31, 2015 44.87M
December 31, 2014 48.45M
September 30, 2014 39.45M
June 30, 2014 40.90M
March 31, 2014 36.97M
December 31, 2013 38.03M
September 30, 2013 26.45M
June 30, 2013 23.25M
March 31, 2013 22.26M
December 31, 2012 23.73M
September 30, 2012 20.52M
June 30, 2012 19.72M
March 31, 2012 21.40M
December 31, 2011 21.15M
September 30, 2011 14.28M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

102.60M
Minimum
Sep 2019
315.60M
Maximum
Mar 2023
198.14M
Average
190.70M
Median
Sep 2021

SG&A Expense (Quarterly) Benchmarks

Novartis AG 3.444B
MorphoSys AG -9.867M
Illumina Inc 485.00M
Biogen Inc 608.50M
Pfizer Inc 4.575B